Navigation Links
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
Date:11/7/2007

n-Janssen.

About Centocor

Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis.

The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients suffering from debilitating immune disorders. Centocor, Inc. is a wholly owned subsidiary of Johnson & Johnson.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2006. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result
'/>"/>

SOURCE Centocor Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...all/--KeryxBiopharmaceuticals,Inc.(Nasdaq: KERX )t...tiveOfficer,isscheduledtopresentatthePiperJaffray2...y. ,, Mr.Bentsur,spresentationwillbewebcastlive...blefromtheInvestorInformationpageoftheCompany,sWeb...onofthewebcastwillbeavailablefollowingtheconclusio...
(Date:11/24/2009)...FirstCall/--BioSpecificsTechnologiesCorp.(Nasdaq: ...lasscollagenase-basedproducts,todayannouncedthatBi...omingPiperJaffray21stAnnualHealthCareConferenceonT...HotelinNewYork,NY. ,, Alivewebcastofthepresenta...torRelationssectionoftheCompany,swebsiteat www.bio...
(Date:11/23/2009)...ewswire/--FebeDurango-Rueda,52,aColombiannational,...etodefraudtheExport-ImportBankoftheUnitedStates(Ex...rneyGeneraloftheCriminalDivisionLannyA.BreuerandAc...k,OfficeoftheInspectorGeneral. ,, Durangopleade...urtinWashingtontoaone-countcriminalinformationchar...
Breaking Medicine Technology:Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Colombian National Pleads Guilty to Role in Defrauding the Export-Import Bank of the United States of More Than $1 Million 2Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350 5272 1Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350 5272 2High sensitivity bone marrow aspiration technology enhances leukemia cell detection 58991 1High sensitivity bone marrow aspiration technology enhances leukemia cell detection 58991 2Keeping DNA all in the family 10277 1Keeping DNA all in the family 10277 2Keeping DNA all in the family 10277 3
...irst to Show RNA Aptamer Drug:Antidote Pair Offers...nts with Coronary Artery ...ciences today announced,the journal Circulation ha...anticoagulation system Phase 1b dose-escalation st...n aptamer-based anticoagulant, RB006,and its match...
... an editorial,commentary(1) in the current issue o...ndent experts on cytomegalovirus (CMV) said the va...daq: VICL ), at the optimal dose and,regimen test... persistent,immune responses in a majority of CMV-...tion for its potential to prevent infection and di...
Other Medicine Technology:Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System 2Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System 3Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System 4Promise of Vical's CMV Vaccine Noted by Independent Experts 2Promise of Vical's CMV Vaccine Noted by Independent Experts 3Promise of Vical's CMV Vaccine Noted by Independent Experts 4
(Date:11/24/2009)...ith his state-of-the-art website, Dr. Richard Cumm...t with patients and share information about his N...ocedures that he offers. , ...h Carolina plastic surgeon Dr. Richard Cummings h...ook to expand his reach and keep an ongoing dialog...
(Date:11/24/2009)... Lintner is embracing the latest tools of virtual ...ing dialogue with patients. Through Facebook, Twit...rovides information about his Atlanta plastic sur...hat patients may have. , ...c surgeon in Atlanta is taking full advantage of ...
(Date:11/24/2009)...Pense World Volunteer Computing Team has joined th...um Monte Carlo method to problems in Quantum Chemi...nt in life science research. This project joins Fo...home (gravity wave detection), and GPUGrid (molec... (PRWEB) November 24, 2009 -- G...
(Date:11/24/2009)...Removal Laser Clinic, located in San Diego, is hel..., with his new modeling career. The race to remove...ull time in the middle of 2010 is on. , ... Removal Laser Clinic, located in San Diego, is he...n, with his new modeling career. The race to remov...
(Date:11/24/2009)...ed by Opticom Data Research, FloatScope is a hand-... eye. , New Westminster, ...w hand-held device for self-examination of the eye...h conditions such as floaters and opacities in the... the iris., , , FloatScope uses a beam of light f...
Breaking Medicine News(10 mins):Health News:North Carolina Plastic Surgeon Embracing Social Media to Connect with Patients and Reach Out to Community 2Health News:North Carolina Plastic Surgeon Embracing Social Media to Connect with Patients and Reach Out to Community 3Health News:Atlanta Plastic Surgeon Using Social Media To Connect with Patients 2Health News:Atlanta Plastic Surgeon Using Social Media To Connect with Patients 3Health News:GeoPense Announces it has Joined QMC@home Project 2Health News:Tattoo Removal on the Fastest U.S. Marine 2Health News:FloatScope - A New Device for Self-Viewing Eye Floaters 2
... more acidic, ocean creatures are undergoing sever...ng to scientists at a press briefing this morning ...for the Advancement of Science in Boston. , Gret...here she collected pteropods, tiny marine snails t...
...istant Killers of the 21st Century , WHO: , Sal..., Thomas Lietman, University of California, San Fr...rlos Castillo-Chavez, Arizona State University , ...EN: 8:30-11:30 a.m., Sunday, Feb. 17 , WHERE: S...
...t different strategies for curbing hospital-acquir...and patient isolation may be effective approaches ...a. , In an era of superbugs, such as methicillin-...velop policies and treatment protocols, may reduce...
...ds to be addressed next is the epidemic of pain, a... together to discuss the latest in pain research a...rican Academy of Pain Medicine (AAPM), February 12...smoking and lose weight. Now it is time to focus ...
...lar survival rates to younger cases , , FR...tients can undergo lung transplantation and have g...e patients from having the procedure, a new study ...2 who had lung transplants between March 2000 and ...
..., Proposed Changes in Priorities Cut ... As President Bush begins,a five-country tour of ...he,President,s Emergency Plan for AIDS Relief (PEP...oday cautioned the President,that his legacy as a ...
Other Medicine News:Health News:Small sea creatures may be the 'canaries in the coal mine' of climate change 2Health News:Mathematical modeling offers new approaches to fight dual-resistant hospital infections 2Health News:Physicians focus on stopping pain epidemic 2Health News:Physicians focus on stopping pain epidemic 3Health News:Physicians focus on stopping pain epidemic 4Health News:Physicians focus on stopping pain epidemic 5Health News:Physicians focus on stopping pain epidemic 6Health News:Good Outcomes Possible for Older Lung Transplant Patients 2Health News:Bush AIDS Legacy at Risk, Says AHF 2
Bander Ureteral Diversion Stent Sets - SOF-FLEX®
...the urinary tract. The nitinol memory wire allows ...orsion. The unique tipless design aids in calyceal...he base of the calyx and encircle the stone. The t...mage and perforation. The 2.2, 3.0 and 3.2 French ...
ECN-1530 - Video Choledoco-Nephroscope
C-FLEX® Stent Sets
Medicine Products: